首页> 外文期刊>Orthopaedic Journal of Sports Medicine >A Cost-Effectiveness Analysis of Surgical Treatment Modalities for Chondral Lesions of the Knee: Microfracture, Osteochondral Autograft Transplantation, and Autologous Chondrocyte Implantation
【24h】

A Cost-Effectiveness Analysis of Surgical Treatment Modalities for Chondral Lesions of the Knee: Microfracture, Osteochondral Autograft Transplantation, and Autologous Chondrocyte Implantation

机译:膝关节软骨病变的手术治疗方式的成本-效果分析:微骨折,骨软骨自体移植和自体软骨细胞移植

获取原文
           

摘要

Background: Numerous surgical options exist to treat chondral lesions in the knee, including microfracture (MFx), osteochondral autograft transplantation (OAT), first-generation autologous chondrocyte implantation (ACI-1), and next-generation ACI (ACI-2). Purpose: To compare the cost-effectiveness of MFx, OAT, and ACI-1. The secondary purpose of this study was to compare the functional outcomes of MFx, OAT, ACI-1, and ACI-2. Study Design: Systematic review; Level of evidence, 2. Methods: Two independent reviewers conducted an online literature search of 2 databases for level 1 and 2 studies using the Lysholm, International Knee Documentation Committee (IKDC), Knee injury and Osteoarthritis Outcome Score (KOOS), and/or Hospital for Special Surgery (HSS) Knee Score. A weighted mean difference in pre- to postoperative functional outcome score was calculated for each treatment. The mean per-patient costs associated with MFx, OAT, and ACI-1 were determined from a recent publication based on review of a national private insurance database. The cost for each procedure was then divided by the weighted mean difference in functional outcome score to give the cost-per-point change in outcome score. Results: A total of 12 studies (6 level 1, 6 level 2) met the inclusion criteria for the functional outcome analysis, including 730 knees (MFx, n = 300; OAT, n = 90; ACI-1, n = 68; ACI-2, n = 272). The mean follow-up was not significantly different between groups (MFx, 29.4 months; OAT, 38.3 months; ACI-1, 19.0 months; ACI-2, 26.7 months). The mean increase in functional outcome score was 23 for MFx, 19 for OAT, 20 for ACI-1, and 35 for ACI-2. The change in functional outcome score was significantly greater for ACI-2 when compared with all other treatments ( P < .0001). The cost-per-point change in functional outcome score was $200.59 for MFx, $313.84 for OAT, and $536.59 for ACI-1. Conclusion: MFx, OAT, ACI-1, and ACI-2 are effective surgical procedures for the treatment of cartilage defects in the knee. All 4 treatments led to an increase in functional outcome scores postoperatively with a short-term follow-up. ACI-2 had a statistically greater improvement in functional outcome scores as compared with the other 3 procedures. MFx was found to be the most cost-effective treatment option and ACI-1 the least cost-effective.
机译:背景:存在许多治疗膝关节软骨病变的手术选择,包括微骨折(MFx),自体骨软骨移植(OAT),第一代自体软骨细胞植入(ACI-1)和下一代ACI(ACI-2)。目的:比较MFx,OAT和ACI-1的成本效益。这项研究的次要目的是比较MFx,OAT,ACI-1和ACI-2的功能结果。研究设计:系统评价;证据级别,方法2。方法:两名独立评论者使用Lysholm,国际膝关节文献委员会(IKDC),膝关节损伤和骨关节炎结果评分(KOOS)和/或对2个数据库进行了在线文献搜索,以进行1级和2级研究特殊外科医院(HSS)膝关节评分。计算每种疗法术前至术后功能结局评分的加权平均差异。与MFx,OAT和ACI-1相关的平均每位患者费用是根据对国家私人保险数据库的审查从最近的出版物中确定的。然后,将每个过程的成本除以功能性结果得分的加权平均差,得出结果得分的每点成本变化。结果:共有12项研究(6级1级,6级2级)符合功能结果分析的纳入标准,包括730膝(MFx,n = 300; OAT,n = 90; ACI-1,n = 68; ACI-1,n = 68; Ax-1,n = 68; Ax-1,n = 68。 ACI-2,n = 272)。各组之间的平均随访无显着差异(MFx,29.4个月; OAT,38.3个月; ACI-1,19.0个月; ACI-2,26.7个月)。 MFx功能预后评分的平均增加是23,OAT是19,ACI-1是20,ACI-2是35。与所有其他治疗相比,ACI-2的功能结局评分变化明显更大(P <.0001)。功能结局评分的每点成本变化对于MFx为200.59美元,对于OAT为313.84美元,对于ACI-1为536.59美元。结论:MFx,OAT,ACI-1和ACI-2是治疗膝关节软骨缺损的有效手术方法。短期随访后,所有4种治疗均导致术后功能结局评分增加。与其他3种方法相比,ACI-2在功能结局评分方面具有统计学上更大的改善。发现MFx是最具成本效益的治疗选择,而ACI-1是成本最低的治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号